Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 0.68 |
| ▸ | CDK2 | P24941 | 17/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 17/20 | 0.68 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.68 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.57 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30490704 | 0.89 | FLT3 (0.63) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL22467048 | 0.89 | FLT3 (0.63) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL30490744 | 0.87 | FLT3 (0.72) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL22466882 | 0.87 | FLT3 (0.72) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL22466838 | 0.87 | FLT3 (0.65) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL30490656 | 0.87 | FLT3 (0.65) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL30490774 | 0.84 | FLT3 (0.71) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL22466910 | 0.84 | FLT3 (0.71) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL22477874 | 0.84 | FLT3 (0.71) | FLT3CDK2CCNA1STING1PBK | |
| SCHEMBL22478078 | 0.82 | FLT3 (0.72) | FLT3CDK2CCNA1STING1PBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233859-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | Purdue Research Foundation (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3600287-B1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2021-12-02 | — | — | US | disclosed |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION | 2021-06-22 | — | — | US | disclosed |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.